Yoon Jun Kim: Clinical Trials

1 trial sponsored by Yoon Jun Kim, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 recruiting. 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11Recruiting 1
Phase 21Recruiting 1

Follow Yoon Jun Kim: new trials by email

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
Tremelimumab Plus Durvalumab (MEDI4736), Transarterial chemoembolization (TACE) - Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma
Phase 1 / Phase 2RecruitingYoon Jun Kim242025-04-182025-05-14

Conditions studied

Carcinoma, Hepatocellular (1)

Interventions

durvalumab (1)  ·  tremelimumab (1)

Countries

South Korea (1)